Thyroid cysts, liver cysts, kidney cysts–Ultra-minimally invasive sclerotherapy

  What is the minimally invasive sclerotherapy technique for cysts, i.e., the sclerosing agent (polyglaucine and other injections) is injected into the cystic cavity through ultrasound-guided percutaneous puncture technique or percutaneous stoma shunt method, which can make the cyst gradually shrink, disappear and eliminate the symptoms to achieve the treatment purpose.  The advantages of this technology for the treatment of cystic lesions minimally invasive, repeatable treatment, no scar on the body surface, does not affect the aesthetics intraoperative, postoperative patient pain is light, fast recovery most patients can be treated in the outpatient clinic, does not affect normal work and life less expensive than traditional surgical treatment, reduce the economic burden of patients significant efficacy, safe and reliable The need for sclerotherapy of cystic thyroid nodules is more common, mostly follicular nodules cystic degeneration, infection or The majority of these nodules are benign, and their incidence is closely related to ageing. When the lesion develops faster and larger, it will not only affect the aesthetics, but also produce compression symptoms on the neighboring organs, especially when there is acute bleeding or infection in the capsule, it will cause more obvious acute symptoms such as neck swelling, foreign body sensation and even severe pain, which should be given timely and effective treatment.  Indications: 1) no previous thermal ablation treatment such as microwave ablation, radiofrequency ablation, laser ablation, etc. 2) nodules with maximum cystic cavity diameter greater than 2 cm 3) a history of more than 3 months (during which the cystic cavity becomes larger or does not shrink significantly) or a short history of the disease but pain and/or serious aesthetic impact patients with a strong desire for treatment.  Contraindications:Ultrasonography shows the presence of components suspected of malignant lesions such as sand-like calcifications in the capsule and confirmed by cytopathology those with a history of alcohol allergy those with severe coagulation mechanism disorders who have recently used cephalosporins The need for sclerotherapy of hepatic and renal cysts Hepatic cysts: when the diameter is greater than 5 cm or in some specific areas (left lobe of the liver) can squeeze the gastric sinus or duodenum causing gastrointestinal symptoms such as abdominal distension and epigastric discomfort, the cyst can Infection or rupture and bleeding renal cysts: when the diameter is greater than 5 cm or at certain special sites (convex to the renal pelvis or parapelvis), there can be symptoms such as lumbar distension and pain, infection, hematuria or squeezing the renal pelvis and ureter causing hydronephrosis: Tumor cysts cannot exclude aneurysm cystic lesions with a history of alcohol allergy, serious bleeding tendency, bleeding and coagulation mechanism disorders, cysts with biliary tract, renal pelvis traffic, serious impairment of kidney function, puncture path can not avoid large blood vessels, bile ducts and other important organs, or cysts located in areas not easily reached by puncture polycystic liver, polycystic kidney, unless the larger cysts compression of the surrounding organs due to comorbidities, generally not sclerotherapy Recently used cephalosporin ultrasound-guided cystic nodule sclerotherapy follow-up Efficacy assessment: review at 1 month, 3 months, 6 months and 12 months after surgery to observe the volume of the residual cystic cavity of cystic nodules, and judge the efficacy and prognosis according to the rate of cystic nodule reduction.